New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:07 EDTXNCRXencor's asthma candidate shows posive results in preclinical study
Xencor will present preclinical data comparing activity of XmAb7195 to omalizumab in reducing IgE, a protein responsible for triggering disease activity in asthma and other allergic disorders. The study supports future studies in human clinical trials. The results of the study found that after a single 5 mg/kg intravenous dose of XmAb7195 or omalizumab in chimpanzees, XmAb7195 reduced free IgE to at least 10-fold lower levels than omalizumab. Similar to its effects in humans, omalizumab increased total IgE. In contrast, XmAb7195 rapidly depleted total IgE below quantifiable levels within 1 hour.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
08:49 EDTXNCRUpdate: Xencor 7.5M share Secondary priced at $14.25
Subscribe for More Information
06:24 EDTXNCRXencor 5.5M share Secondary priced at $14.25
The deal size was increased to 7.5M shares from 5.5M shares. Leerink acted as lead book running manager for the offering.
February 23, 2015
19:44 EDTXNCRXencor to participate in a conference call with Leerink
Subscribe for More Information
16:08 EDTXNCRXencor files to sell 5.5M shares of common stock
Subscribe for More Information
February 19, 2015
16:18 EDTXNCRXencor sees sufficient cash to fund R&D through 2016
Subscribe for More Information
16:18 EDTXNCRXencor reports Q4 revenue $5.7M, consensus $2.22M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use